Effects of Monascin on Anti-inflammation Mediated by Nrf2 Activation in Advanced Glycation End Product-Treated THP‑1 Monocytes and Methylglyoxal-Treated Wistar Rats

• Published in: Journal of agricultural and food chemistry Vol. 61; no. 6; pp. 1288 - 1298
• Main Authors: Lee, Bao-Hong, Hsu, Wei-Hsuan, Huang, Tao, Chang, Yu-Ying, Hsu, Ya-Wen, Pan, Tzu-Ming
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 13.02.2013
• Subjects: Animals; Anti-Inflammatory Agents - administration & dosage; antioxidant activity; Cell Line; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - genetics; Diabetes Mellitus, Type 2 - immunology; glycation; Glycation End Products, Advanced - immunology; heme oxygenase (decyclizing); Heterocyclic Compounds, 3-Ring - administration & dosage; Humans; hyperglycemia; inflammation; Male; monocytes; Monocytes - drug effects; Monocytes - immunology; NF-E2-Related Factor 2 - genetics; NF-E2-Related Factor 2 - immunology; noninsulin-dependent diabetes mellitus; Pyruvaldehyde - immunology; Rats; Rats, Wistar; retinoic acid; silymarin; tumor necrosis factor-alpha; Up-Regulation; methylglyoxal; silymarin; nuclear factor-erythroid 2-related factor-2; receptor for advanced glycation end product; monascin; retinoic acid receptor-α

Hyperglycemia is associated with advanced glycation end products (AGEs). This study was designed to evaluate the inhibitory effects of monascin on receptor for advanced glycation end product (RAGE) signal and THP-1 monocyte inflammation after treatment with S100b, a specific ligand of RAGE. Monascin...